do not combine dpp-4 inhibitors with glp-1 receptor agonists recommendation DPP4 vs | June 2021 | Clinical Corner GLP-1 receptor agonists and DPP-4

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)

22,23 In the liver, GLP-1RAs can also decrease hepatic gluconeogenesis and enhance glucose uptake, which can improve circulating glucose levels

You can learn more about compounded semaglutide here

(v) promotion of autophagy

Common claims involve gastroparesis and gallbladder issues

The initial dosing regimen of liraglutide is 0.6 mg subcutaneously daily, with the dose increased to up to 3 mg for Saxenda and 1.8 mg for Victoza , usually after one week at the previous dose